Shanghai builds a merger and reorganization head company, and Ning Wang magnifies the move. The bull market still needs to be believed.However, it is a great pity that the China stock market has never had a history of retail investors and institutions getting rich together. Don't deal with hot money and quantification! Foreign investment in A-shares has also become stale and has become fond of speculation. There are always too many routines to create A shares, which is too tiring to play, and the experience is really bad.However, it is a great pity that the China stock market has never had a history of retail investors and institutions getting rich together. Don't deal with hot money and quantification! Foreign investment in A-shares has also become stale and has become fond of speculation. There are always too many routines to create A shares, which is too tiring to play, and the experience is really bad.
Haineng Industry: The controlling shareholder intends to reduce the company's shares by no more than 3%;China Research Institute: Wang Xiuyun reduced its shareholding by 1%. At present, the company has not directly involved in the application field of humanoid robots.Before, I said that institutions don't believe in bull market, but now I don't believe in many sizes, so investors are doing their best to support the stock market. Now every time it goes up, bosses of all sizes are reducing their holdings, including big funds, which are frequently cashed out ...! This will hit everyone's confidence in holding shares.
Recently, all localities are vigorously promoting mergers and acquisitions, first in Shenzhen and then in Shanghai, and it is estimated that Beijing will soon. The listed companies in the north and Shenzhen are all active, and the merger of Shanghai benchmark brokerage Haitong+Guotai Junan has landed! Other places will follow suit, but mergers and acquisitions are really difficult to grasp, and it is estimated that there are more local+state-owned assets.Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.First, heavy! Shanghai merger and reorganization action plan announced
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14